

December 27, 2024
 SymBio Pharmaceuticals Limited
 Fuminori Yoshida
 Representative Director
 President and Chief Executive Officer
 (Securities Code: 4582)

Notice of Personnel Changes at SymBio Pharma USA, Inc.

TOKYO, December 27, 2024 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, “SymBio” or the “Company”) today announced the appointment of Masaru Taguchi as Director and President and Chief Executive Officer of SymBio Pharma USA, Inc. (established in May 2016; wholly owned US subsidiary, “SymBio Pharma USA”), effective January 1, 2025. Going forward, SymBio Pharma USA will be the strategic base for the global brincidofovir (“BCV”) business, with full-scale operations to accelerate the development of BCV and achieve commercialization at the earliest possible timing.

Statement from Masaru Taguchi: “I am very honored to join the leadership team of SymBio Pharma USA, the base of global development and commercialization for BCV. I resonate our company’s mission to develop and provide new drugs for underserved therapeutic areas, where the medical needs are extremely high but the development of new therapies is lacking due to the small number of patients, thereby making a substantial contribution to medical care and to the sound development of the pharmaceutical industry. With the support of our team of experts, both within and outside SymBio and SymBio Pharma USA, we will develop our BCV global business platform and become a true global specialty pharmaceutical company.”

Statement from Fuminori Yoshida, President and CEO: “Mr. Taguchi brings extensive experience in the medical field and has a track record of establishing overseas subsidiaries and expanding the global businesses at leading pharmaceutical companies. We expect him to lead the global business of BCV towards 2030.”

SymBio Pharma USA, Inc. (summary)

Name	SymBio Pharma USA, Inc. (SPU)
Address	Durham, North Carolina, USA
Representative	Masaru Taguchi
Establishment Date	May 10, 2016
Shareholders	A 100% subsidiary of SymBio Pharmaceuticals Limited
Business Activities	Research and development of pharmaceutical products

1. Name and Title

Name	Title
Masaru Taguchi	President and Chief Executive Officer of SPU

2. Date of appointment: January 1, 2025

3. Profile of the newly appointed President and CEO of SPU

1996	Otsuka Pharmaceutical Co., Ltd. Medical Sales Representative
2003	Otsuka America Pharmaceutical, Inc. Global Marketing Manager of the CNS product, Abilify
2010	Otsuka Canada Pharmaceutical Inc. General Manager
2017	Otsuka Pharmaceutical Co., Ltd. General Manager, Diagnostic Division
2018	Otsuka Electronics Co., Ltd. President and Representative Director
2020	Philips Japan, Connected Care Business Marketing & Sales Leader
2024	Philips Japan, Monitoring and Connected Care Business Leader and Enterprise Informatics Business Leader
2024 November	Join SymBio Pharmaceuticals Ltd., Corporate Officer and Assistant to President
1996	Graduated from the Degree of International Relations, University of Wisconsin-Whitewater

About SymBio Pharmaceuticals Limited.

SymBio Pharmaceuticals Limited was established in March 2005 by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. In May 2016, the Company incorporated its wholly owned subsidiary in the U.S., called SymBio Pharma USA, Inc. (Headquarters: Durham, North Carolina). The Company’s underlying corporate mission is to “deliver hope to patients in need” as it aspires to be a leading global specialty biopharmaceutical company dedicated to addressing underserved medical needs.

[Contact]

Investor Relations

Tel: +81(0)3 5472 1125